Carolyn Westhoff, MD, Columbia University, New York, NY
The purpose of this study is to learn how two different medications affect the breast: an estrogen-free selective progesterone-receptor modulator called UPA vs. a low-dose oral contraceptive pill. This is a randomized, phase I clinical trial. Participants have a 50% chance of receiving the UPA pill, and 50% chance of receiving the low-dose oral contraceptive.
The initial Call to Action for this study was sent to AOW members on August 9, 2017 and the researchers closed enrollment in November of 2019. The AOW provided them with 13 women who were interested in enrolling in the study.